Elan Shares, Alzheimer's Hopes Take Hit
Shares of Irish drugmaker Elan (ELN) took a hit Friday along with hopes for a new Alzheimer's treatment, as four patients in a French study came down with potentially serious symptoms.
"While the vaccine represents a potential breakthrough treatment approach if successful, last night's disclosure raises legitimate concerns about the viability of the program, which is very important to the long-term outlook of Elan," said David Steinberg, an analyst at Deutsche Banc Alex. Brown, in a research note. He lowered his recommendation on Elan to market perform from buy, cutting his price target to $42.
Elan said it would temporarily halt patient dosing in a Phase 2A study of its Alzheimer's vaccine candidate after four of 97 patients in France were reported to have clinical signs consistent with inflammation in the central nervous system. The cause of the symptoms remains unknown.
Elan ended down $6.15, or 13.7%, to $38.65; it was the fifth most active stock on the New York Stock Exchange. Other firms to downgrade Elan included SG Cowen and RBC Capital Markets.
Standard Approach"Our decision to temporarily suspend further dosing, pending the results of our evaluation, is a standard approach to protect the safety of patients in clinical trials," said Dr. Ivan Lieberburg, chief scientific and medical officer at Elan, in a written statement Thursday. "A decision will be made on resumption of dosing pending the outcome of this investigation." Elan and Wyeth-Ayerst Laboratories, the pharmaceutical division of American Home Products (AHP), are conducting clinical trials for the drug, AN-1792, in the U.S. and Europe in patients with Alzheimer's disease. American Home Products shares ended down 38 cents, or 0.6%, at $61.92. According to Steinberg, the Alzheimer's drug is one of the reasons people own Elan's stock and was a basis for his maintaining a buy rating until now. "We've always been excited about the prospects of this product, but this puts a cloud over the situation," Steinberg said. If it got to market, he said, the drug could be a billion-dollar product.
Final StrawStill, Steinberg said the announcement was the "final straw" and led him to downgrade. He said delays and disappointments in four separate products, worries about generic competition for the company's two largest-selling products, and questions about the quality of the company's earnings were also factors. From a valuation standpoint, Elan looks inexpensive, Steinberg said. The company is currently trading at a
DefendersAndrew Forman, an analyst at Friedman Billings Ramsey, said in a research note that the fact that viral infections, which can cause inflammation, were found in some of the patients could mean the reaction wasn't related to the drug. He also noted that the cases were isolated to one clinical center. Even if the reactions were related to the drug, Forman said: "This is a vaccine where immune responses are expected. And Phase 2 trials are inherently dose-ranging studies, which often result in side effects, usually at the higher levels." Forman also noted Elan's other Alzheimer's programs and touted the stock's valuation: "Given that any revenue form this program is unlikely before 2006 and that the stock was already trading at 20 times our 2002 earnings-per-share estimate before this news, we believe Elan shares are now extremely undervalued."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV